Browsing Tag
azer-cel
4 posts
Imugene (ASX:IMU) jumps 19% as azer-cel opportunity meets a funding reset
Imugene Limited shares jumped 18.92% to A$0.044 on October 5 as trading activity accelerated from a 52-week low. The rebound puts azer-cel, Imugene's sharply reduced cost base and its recently replenished funding runway back in focus.
$IMU rises after Imugene wins FDA Fast Track status for allogeneic CAR T therapy in CLL and MZL
Imugene won FDA Fast Track status for azer-cel in blood cancers. Find out what the $IMU regulatory boost means for investors.
Is Imugene’s 17% stock slump an overreaction to dilution or a warning sign for CAR T investors?
Imugene shares fell 17% after a $37.5M raise, but can Fast Track and strong azer-cel data make the drop a buying opportunity for CAR T investors?
Imugene’s A$37.5m capital raise fuels pivotal azer-cel trial plans as stock tumbles 17%
Imugene raises A$37.5M to fund pivotal azer-cel trial in 2026. Can its off-the-shelf CAR T therapy deliver on its $2B market promise?